Data released this week by the European Centre for Disease Prevention and Control (ECDC) and European Food Safety Authority (EFSA) reveal that antimicrobials used to treat diseases that can be transmitted between animals and humans, such as campylobacteriosis and salmonellosis, are becoming less effective.
Vytenis Andriukaitis, EU Commissioner for Health and Food Safety, said: “The report released today should ring–again–alarm bells. It shows that we are entering into a world where more and more common infections become difficult–or even sometimes impossible–to treat. However, ambitious national policies in some countries limiting antimicrobial use have led to a decrease of antimicrobial resistance. So before the alarm bells become a deafening siren, let’s make sure that we increasingly act all together, in every country and across the public health, animal health and environment sectors under the One Health approach umbrella.”
According to the report, which refers to 2017 data, resistance to fluoroquinolones (such as ciprofloxacin) is so high in Campylobacter bacteria in some countries that these antimicrobials no longer work for the treatment of severe campylobacteriosis cases.
Most countries reported that Salmonella in humans is increasingly resistant to fluoroquinolones. Multidrug resistance (resistance to three or more antimicrobials) is high in Salmonella found in humans (28.3%) and animals, particularly in S. Typhimurium.
Madam Therapeutics believes that an integral, multi-sectoral, multidisciplinary, and global approach to control these – often life-threatening – infections is essential. This means that the world needs to combine forces to work on sustainable usage of antimicrobials through stewardship programs, development new antimicrobials, and development of new rapid detection platforms to diagnose AMR infections. Madam Therapeutics is contributing to such an integral approach through the development of novel effective antimicrobial agents and strategies to limit and counteract the development of resistance will be developed. Only when used in combination, these innovations will have a major impact by preventing AMR development and the associated costs for health care systems. Madam Therapeutics is therefore actively involved in public private collaborations that promote such an integrated approach.